MarketPulse
T

$TEM

8 articles found
7 positive
0 negative
1 neutral
The Motley FoolThe Motley Fool··Jeff Siegel

Three AI-Powered Healthcare Firms Positioned to Disrupt Medicine by 2030

Three tech-driven companies—Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics—are positioned to reshape healthcare through AI, precision medicine, and faster drug discovery by 2030.
AXSMRXRXTEMCNS disordersprecision medicine
BenzingaBenzinga··Globe Newswire

Pathos AI Acquires DeuterOncology to Commercialize Next-Gen MET Inhibitor

Pathos AI acquires majority stake in DeuterOncology to advance DO-2, a MET inhibitor showing 100% tumor shrinkage in Phase 1 with superior safety profile.
AZNTEMPhase 1 clinical trialoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

AI Clinical Trial Tool Market to Hit $2.76B by 2030 as Protocol Optimization Accelerates

AI clinical trial feasibility market expands from $0.83B (2025) to $2.76B by 2030 at 27.3% CAGR, driven by precision medicine and decentralized trials.
IQVVEEVTEMprecision medicinepredictive analytics
BenzingaBenzinga··Nabaparna Bhattacharya

Quantum, Nuclear, and Fintech Surge: Ten Large-Caps Rally on Sector Tailwinds

Large-cap stocks rallied sharply April 13-17, with IonQ (+62.86%), Oklo (+33.35%), and Robinhood (+33.22%) leading gains driven by DARPA contracts, nuclear momentum, and crypto strength.
OKLOAFRMIONQIONQ.WSRVMD+11cryptocurrencynuclear power
BenzingaBenzinga··Vandana Singh

Tempus AI Surges on AACR Data Windfall Despite Jefferies Skepticism

Tempus AI shares jumped 7.3% to $49.34 after 31 cancer research abstracts were accepted for AACR conference, though analyst coverage turns cautious.
TEMcolorectal cancerprecision medicine
BenzingaBenzinga··Vandana Singh

Tempus Expands Merck Partnership as AI Precision Medicine Gains Momentum

Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.
MRKTEMpersonalized medicineoncology
BenzingaBenzinga··Prnewswire

AI-Powered Cardiac Imaging Reshapes Hospital Economics as $20B Market Emerges

Hospital networks deploy AI cardiac imaging to cut costs and improve outcomes. Market projected to hit $20B by 2033, with major players like GE HealthCare and Butterfly Network leading expansion.
GEHCRDNTTEMBFLYAI-enhanced cardiac imagingechocardiography
BenzingaBenzinga··Lekha Gupta

Tech Giants Navigate Trade Turbulence as AI Race Intensifies

US-Taiwan tensions escalate amid tariff shifts. Amazon invests $12B domestically while Apple relocates Mac production to Texas. AI developments dominate sector headlines.
NVDAAMDMETAMSFTAMZN+22AI investmentautonomous vehicles